SOAT1 and prostate carcinoma: Given the known impact of JAK-STAT signaling on tumor survival, proliferation, and invasion, this pathway has been considered as a therapeutic target in various cancers, such as hematological cancer 33, breast cancer 34, prostate cancer 35, and brain cancer 36.